QTRX: Diagnostics and clinical trials growth, new leadership, and synergy gains drive optimism for 2024Quartr·1 day ago, 01:25 PMAKYA0.00%QTRX-2.39%
Quanterix Corp 2026: Revenue $32.91M, EPS ($1.04) — 10-Q SummaryTradingView·Aug 10 at 07:41 AMQTRX-2.39%AKYA0.00%
Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026 | QTRX Stock NewsStockTitan·Apr 23 at 11:35 PMQTRX-2.39%
Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026 | QTRX Stock NewsStockTitan·Feb 19 at 11:33 PMQTRX-2.39%AKYA0.00%
Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum | QTRX Stock NewsStockTitan·Jul 8, 2025 at 08:07 AMAKYA0.00%QTRX-2.39%
18:18 ET AKOYA BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYAprnewswire·Jun 20, 2025 at 05:19 PMAKYA0.00%
Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal | AKYA Stock NewsStockTitan·May 23, 2025 at 01:21 PMAKYA0.00%QTRX-2.39%
Akoya Biosciences reveals Q1 2025 financial performance with promising numbers.Unusual Whales·May 12, 2025 at 03:28 PMAKYA0.00%
Akoya Biosciences | 8-K: FY2025 Q1 Revenue Misses Estimate at USD 16.64 MEarnings Watch·May 12, 2025 at 03:11 PMAKYA0.00%
